Use of pharmacological inhibitors of γ-secretase (GSI) and β-secretase (BSI) indicate that a metabolite of APP other than Aβ may be responsible for the cognitive deficits in FDDKI mice. The gene discussed is APP; the disease is Cognitive impairment.